Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Author: AkedaYukihiro, NagaiHideaki, OhshimaNobuharu, OishiKazunori

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed the immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in a cohort of 16 elderly patients with chronic lung diseases. It found that the vaccine induced significant increases in serotype-specific IgG and opsonization index after all three vaccinations. While local and systemic reactions were more frequent after the second and third vaccinations, no serious systemic reactions were observed.
Paper Details　
Original Abstract of the Article :
An observational study to assess immunogenicity before and after the first, second, and third vaccinations with the 23-valent pneumococcal polysaccharide vaccine in a cohort of 16 elderly patients with chronic lung diseases was conducted. The safety of this vaccine was also compared between the firs...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553684/

データ提供：米国国立医学図書館（NLM）

The Third Time's the Charm? Pneumococcal Vaccination in the Elderly

In the vast desert of healthcare, where we strive to protect vulnerable populations, vaccination plays a crucial role. This study delves into the world of pneumococcal vaccination, specifically examining the effectiveness and safety of a third dose in elderly patients with chronic lung diseases. The researchers conducted an observational study to assess the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in this high-risk population.

Boosting Immunity with a Third Dose

The study findings suggest that a third dose of PPSV23 can significantly increase the levels of serotype-specific IgG, a type of antibody that plays a critical role in fighting infection. The researchers also found that the third dose was well-tolerated, with minimal adverse events. These findings support the use of a third dose of PPSV23 in elderly patients with chronic lung diseases to strengthen their immune system and provide greater protection against pneumococcal infections.

Protecting the Elderly from Pneumococcal Infections

Pneumococcal infections can be particularly serious in elderly patients, especially those with underlying health conditions. This study provides valuable insights into the benefits of a third dose of PPSV23, which can help to reduce the risk of these infections. By getting vaccinated, elderly individuals can help to protect themselves and enhance their overall health and well-being. Just as a camel adapts to the harsh conditions of the desert, a strong immune system helps us navigate the challenges of life and stay resilient.

Dr.Camel's Conclusion

This study provides compelling evidence for the effectiveness and safety of a third dose of PPSV23 in elderly patients with chronic lung diseases. By boosting their immune system, this vaccination strategy can help to protect this vulnerable population from serious pneumococcal infections. As we continue to explore the vast desert of healthcare, vaccinations are a vital tool for safeguarding health and well-being.
Date :
  1. Date Completed 2021-06-21
  2. Date Revised 2021-06-21
Further Info :

Pubmed ID

32048894

DOI: Digital Object Identifier

PMC7553684

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.